B7-H1 AND SURVIVIN IN CANCER

• US 20100015642A1
• Filed: 01/05/2007
• Published: 01/21/2010
• Est. Priority Date: 01/05/2006
• Status: Abandoned Application

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Thompson, Robert H., Parker, Alexander S., Dong, Haidong, Krambeck, Amy, Kuntz, Susan, Lohse, Christine M., Cheville, John C., Kwon, Eugene D.
• Application Number:
  US12/160,017
• Publication Number:
  US 20100015642A1
• Time in Patent Office: Days
• US Class Current: 435/7.230
• CPC Class Codes: G01N 2333/705 Assays involving receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: G01N 2510/00 Detection of programmed cell death, i.e. apoptosis
• CPC Class Codes: G01N 33/57438 of liver, pancreas or kidney
• CPC Class Codes: G01N 33/57484 involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
• CPC Class Codes: G01N 33/57492 involving compounds localized on the membrane of tumor or cancer cells
• CPC Class Codes: G01N 33/57496 involving intracellular compounds

Abstract

Methods of determining prognosis of a subject with cancer by assessing expression of B7-H1 and survivin in combination.

Claims

1. A method of determining the prognosis of a subject with cancer, said method comprising:

(a) providing a tissue sample from said subject; and

(b) assessing in said tissue sample the presence or absence of expression of B7-H1 and survivin, wherein the presence of expression of B7-H1 and survivin in said tissue sample indicates said subject is more likely to die of the cancer than if B7-H1 and survivin expression is absent or B7-H1 or survivin is singly expressed in the tissue sample.

2. The method of claim 1, wherein expression is assessed by detecting the presence or absence of polypeptide.

3. The method of claim 2, wherein detecting comprises contacting said tissue sample with an antibody that binds to B7-H1 and an antibody that binds to survivin.

4. The method of claim 3, wherein each said antibody is fluorescently labeled.

5. The method of claim 2, wherein detecting comprises fluorescence flow cytometry (FFC).

6. The method of claim 2, wherein detecting comprises immunohistochemistry.

7. The method of claim 1, wherein said tissue sample is selected from the group consisting of lung, epithelial, connective, vascular, muscle, nervous, skeletal, lymphatic, prostate, cervical, breast, spleen, gastric, intestinal, oral, esophageal, dermal, liver, bladder, thyroid, thymic, adrenal, brain, gallbladder, pancreatic, uterine, ovarian, and testicular tissue.

8. The method of claim 7, wherein said tissue sample is renal tissue.

9. The method of claim 1, wherein the cancer is renal cell carcinoma.

10. The method of claim 1, wherein said subject is a human.

11. A method of determining risk of cancer progression in a subject with cancer, said method comprising:

(a) providing a tissue sample from said subject; and

(b) assessing in said tissue sample the presence or absence of expression of B7-H1 and survivin, wherein the presence of expression of B7-H1 and survivin in said tissue sample indicates said subject is at more risk of cancer progression than if B7-H1 and survivin expression is absent or B7-H1 or survivin is singly expressed in the tissue sample.

12. The method of claim 11, wherein expression is assessed by detecting the presence or absence of polypeptide.

13. The method of claim 12, wherein detecting comprises contacting said tissue sample with an antibody that binds to the B7-H1 polypeptide and an antibody that binds to survivin.

14. The method of claim 12, wherein detecting comprises FFC.

15. The method of claim 12, wherein detecting comprises immunohistochemistry.

16. The method of claim 11, wherein said tissue sample is selected from the group consisting of lung, epithelial, connective, vascular, muscle, neural, skeletal, lymphatic, prostate, cervical, breast, spleen, gastric, intestinal, oral, esophageal, dermal, liver, bladder, thyroid, thymic, adrenal, brain, gallbladder, pancreatic, uterine, ovarian, and testicular tissue.

17. The method of claim 16, wherein said tissue sample is renal tissue.

18. The method of claim 11, wherein the subject is a human.

19. An article of manufacture, said article of manufacture comprising a first antibody that binds to a B7-H1 polypeptide and a second antibody that binds to a survivin polypeptide.

20. The article of manufacture of claim 19, wherein said first antibody is labeled with a first label and said second antibody is labeled with a second label, wherein said first and second labels are different.

21. The article of manufacture of claim 20, wherein said first and second labels are fluorescent labels.